MedTrace Logo

Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy

NCT03331302 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-11-04

No results posted yet for this study

Summary

Hyper polarized Xenon-129 MRI will be directly compared to a radioactive Xe-133 scintigraphy to detect defects in lung ventilation from airflow limitation. This study is conducted as a pilot study with intention to conduct a larger clinical trial.

Conditions

Interventions

DRUG

Hyperpolarized Xenon-129 MRI (Experimental)

MRI ventilation scan of the lung with inhaled contrast agent (hyperpolarized Xenon-129)

DRUG

Radioactive Xenon-133 scintigraphy (Active Comparator)

Radioactive ventilation scintigraphy of the lung with inhaled radioactive contrast agent (Xenon-133)

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Yun M Shim, MD · University of Virginia

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2020-06-30
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03331302 on ClinicalTrials.gov